Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HSG4112 in Healthy Female and Obese Subjects
NCT04703764Phase 1Completed
- Sponsor
- Glaceum
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vutiglabridin in obesity (4 arms), sponsored by Glaceum. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Hour 0 to 24, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Point and 10 more. Started Feb 2021; status: completed.
02
Drugs
vutiglabridin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04703764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703764.